Zenas BioPharma, Inc. Common Stock (ZBIO)
PHARMACEUTICAL PREPARATIONS
- Headquarters
- United States
- Employees
- 167
- Market Cap
- $2.0B
About Zenas BioPharma, Inc. Common Stock
Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. The Company manages its operations on a consolidated basis as a single reportable segment focused on the research, development and commercialization of transformative immunology-based therapies.
SentiSense also tracks daily options readings for Zenas BioPharma, Inc. Common Stock: IV rank, put/call percentile, 25-delta skew, open-interest walls, and unusually active contracts, each measured against the stock's own history. Sign in to view them.
Zenas BioPharma, Inc. Common Stock stock analysis, sentiment tracking, and market intelligence on SentiSense.